| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S613711-5mg |
5mg |
期货  |
| |
| S613711-25mg |
25mg |
期货 |
|
| 英文别名 | NCGC00182052-01 | SB19332 | F3390-0301 | SRT1720 - CAS 925434-55-5 | AKOS016001425 | EN300-21319 | N-(2-(3-(1-Piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)-2-quinoxalinecarboxamide | NCGC00182052-06 | 925434-55-5 (free base) | AC-35736 | BDBM502283 |
|---|---|
| 规格或纯度 | Moligand™ |
| 英文名称 | SRT1720 |
| 作用类型 | 激活剂 |
| 作用机制 | sirtuin 1 的激活剂 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide |
| INCHI | 1S/C25H23N7OS/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31/h1-8,13,15-16,26H,9-12,14H2,(H,29,33) |
| InChi Key | IASPBORHOMBZMY-UHFFFAOYSA-N |
| Smiles | C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5 |
| Isomeric SMILES | C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5 |
| PubChem CID | 24180125 |
| 分子量 | 469.57 |
| 分子量 | 469.600 g/mol |
|---|---|
| XLogP3 | 3.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 469.168 Da |
| 单同位素质量Monoisotopic Mass | 469.168 Da |
| 拓扑极表面积Topological Polar Surface Area | 116.000 Ų |
| 重原子数Heavy Atom Count | 34 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 707.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB et al.. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.. Nature, 450 (7170): (712-6). [PMID:18046409] |
| 2. Cheng CY, Gutierrez NM, Marzuki MB, Lu X, Foreman TW, Paleja B, Lee B, Balachander A, Chen J, Tsenova L et al.. (2017) Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis.. Sci Immunol, 2 (9): [PMID:28707004] |
首页
400-620-6333
